Thank you for your mail. Yes, I received my order and everithing is fine
with it. Thank you very much for the four extra pills you had, I really do
appreciate it.
I should recommand your site to friends and I'll come back to you soon.
Medivation Reports First Quarter Financial Results and Provides Corporate Update - MarketWatch (press release)
Medivation Reports First Quarter Financial Results and Provides Corporate UpdateMarketWatch (press release)Continued to enroll patients in the Phase 2 TERRAIN trial, which is comparing the effect of enzalutamide versus bicalutamide, the most commonly used anti-androgen, on progression-free survival in approximately 370 men with advanced prostate cancer who .
MDVN Misses; Focus on Enzalutamide - Zacks.com
MDVN Misses; Focus on EnzalutamideZacks.
New Therapies for Prostate Cancer: The Practicalities - OncLive
OncLiveNew Therapies for Prostate Cancer: The PracticalitiesOncLive12,13 This investigational agent is an irreversible androgen receptor (AR) antagonist and AR signaling inhibitor, and represents an advance from the nonsteroidal AR antagonists flutamide, bicalutamide, and nilutamide.
MDVN Misses; Focus on Enzalutamide - Analyst Blog - NASDAQ
MDVN Misses; Focus on Enzalutamide - Analyst BlogNASDAQEnzalutamide is also in a phase II study (TERRAIN), which will compare enzalutamide with bicalutamide, in advanced prostate cancer patients who have progressed following medical castration with LHRH analog therapy or surgical castration.
CEO Brennan to leave AstraZeneca as profits sink - Pharma Times
CEO Brennan to leave AstraZeneca as profits sinkPharma TimesAs for oncology, Arimidex (anastrozole) fell 39% to $144 million, battered by patent expiries, while Casodex (bicalutamide) fell 17% to $113 million.